Escherichia coli CCUG 52544 is an aerobe, mesophilic prokaryote of the family Enterobacteriaceae.
aerobe mesophilic genome sequence| @ref 20215 |
Last LPSN update
2026-02-09 11:37:19 |
| Domain Bacteria |
| Phylum Pseudomonadota |
| Class Gammaproteobacteria |
| Order Enterobacterales |
| Family Enterobacteriaceae |
| Genus Escherichia |
| Species Escherichia coli |
| Full scientific name Escherichia coli (Migula 1895) Castellani and Chalmers 1919 (Approved Lists 1980) |
| Synonyms (1) |
| 59588 | Oxygen toleranceaerobe |
| @ref | Chebi-ID | Metabolite | Utilization activity | Kind of utilization tested | |
|---|---|---|---|---|---|
| 68374 | 29016 ChEBI | arginine | - | hydrolysis | from API ID32E |
| 68374 | 17057 ChEBI | cellobiose | - | builds acid from | from API ID32E |
| 68374 | 18333 ChEBI | D-arabitol | - | builds acid from | from API ID32E |
| 68374 | 18024 ChEBI | D-galacturonic acid | + | builds acid from | from API ID32E |
| 68374 | 17634 ChEBI | D-glucose | + | builds acid from | from API ID32E |
| 68374 | 16899 ChEBI | D-mannitol | + | builds acid from | from API ID32E |
| 68374 | 30849 ChEBI | L-arabinose | + | builds acid from | from API ID32E |
| 68374 | 18403 ChEBI | L-arabitol | - | builds acid from | from API ID32E |
| 68374 | 62345 ChEBI | L-rhamnose | + | builds acid from | from API ID32E |
| 68374 | 25094 ChEBI | lysine | + | degradation | from API ID32E |
| 68374 | 15792 ChEBI | malonate | - | assimilation | from API ID32E |
| 68374 | 17306 ChEBI | maltose | + | builds acid from | from API ID32E |
| 68374 | 17268 ChEBI | myo-inositol | - | builds acid from | from API ID32E |
| 68374 | 18257 ChEBI | ornithine | + | degradation | from API ID32E |
| 68374 | 18394 ChEBI | palatinose | - | builds acid from | from API ID32E |
| 68374 | Potassium 5-ketogluconate | - | builds acid from | from API ID32E | |
| 68374 | 15963 ChEBI | ribitol | - | builds acid from | from API ID32E |
| 68374 | 30911 ChEBI | sorbitol | - | builds acid from | from API ID32E |
| 68374 | 17992 ChEBI | sucrose | + | builds acid from | from API ID32E |
| 68374 | 27082 ChEBI | trehalose | + | builds acid from | from API ID32E |
| 68374 | 27897 ChEBI | tryptophan | + | energy source | from API ID32E |
| 68374 | 16199 ChEBI | urea | - | hydrolysis | from API ID32E |
| @ref | Value | Activity | Ec | |
|---|---|---|---|---|
| 68374 | alpha-galactosidase | + | 3.2.1.22 | from API ID32E |
| 68374 | alpha-glucosidase | - | 3.2.1.20 | from API ID32E |
| 68374 | alpha-maltosidase | - | from API ID32E | |
| 68374 | arginine dihydrolase | - | 3.5.3.6 | from API ID32E |
| 68374 | beta-galactosidase | + | 3.2.1.23 | from API ID32E |
| 68374 | beta-glucosidase | - | 3.2.1.21 | from API ID32E |
| 68374 | beta-glucuronidase | + | 3.2.1.31 | from API ID32E |
| 68374 | L-aspartate arylamidase | - | 3.4.11.21 | from API ID32E |
| 68374 | lipase | - | from API ID32E | |
| 68374 | lysine decarboxylase | + | 4.1.1.18 | from API ID32E |
| 68374 | N-acetyl-beta-glucosaminidase | - | 3.2.1.52 | from API ID32E |
| 68374 | ornithine decarboxylase | + | 4.1.1.17 | from API ID32E |
| 68374 | urease | - | 3.5.1.5 | from API ID32E |
| @ref | ODC | ADH (Arg) | LDC (Lys) | URE | LARL | GAT | 5KG | LipaseLIP | Phenol red (Acidification)RP | beta GLU | MAN | MAL | ADO | PLE | beta GUR | MNT | IND | N-Acetyl-beta-Glucosaminidasebeta NAG | beta GAL | GLU | SAC | LARA | DARL | alpha GLU | alpha GAL | TRE | RHA | INO | CEL | SOR | alpha-MaltosidasealphaMAL | L-aspartic acid arylamidaseAspA | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 59588 | + | - | + | - | - | + | - | - | + | - | + | + | - | - | + | - | + | - | + | + | + | + | - | - | + | + | + | - | - | - | - | - |
| @ref | Description | Assembly level | INSDC accession | BV-BRC accession | NCBI tax ID | Score | |
|---|---|---|---|---|---|---|---|
| 66792 | 32473_D01 assembly for Escherichia coli NCTC13353 | contig | GCA_900448885   | 562.34206  | 562 | 39.93 | |
| Topic | Title | Authors | Journal | DOI | Year | |
|---|---|---|---|---|---|---|
| Laser-assisted microbial culturomics. | Qu T, Koch L, Mukherjee R, Tu Y, Seidel AL, Puttmann LD, Winkel A, Yang I, Grischke J, Liu D, Wolkers WF, Kittler S, Chichkov B, Stiesch M, Szafranski SP. | Nat Commun | 10.1038/s41467-025-66804-7 | 2025 | | |
| Postbeta-Lactamase-Inhibiting Effect of Sulbactam in Combination with Ceftriaxone on Extended-Spectrum-beta-Lactamase-Producing Escherichia coli. | Wang R, Mi K, Lu A, Zhang C, Sun L, Chen Y, Pan Y, Tao Y, Huang L. | Antibiotics (Basel) | 10.3390/antibiotics14090915 | 2025 | | |
| Establishing the reference broth microdilution MIC method for cefepime-taniborbactam. | Belley A, Cusick SM, Pevear DC, Koeth L, DiFranco-Fisher J, Kothari N, Hawser S, Moeck G. | J Clin Microbiol | 10.1128/jcm.00661-25 | 2025 | | |
| Characterization of sulopenem antimicrobial activity using in vitro time-kill kinetics, synergy, post-antibiotic effect, and sub-inhibitory MIC effect methods against Escherichia coli and Klebsiella pneumoniae isolates. | Maher JM, Huband MD, Lindley JM, Rhomberg PR, Aronin SI, Puttagunta S, Castanheira M. | Microbiol Spectr | 10.1128/spectrum.01898-24 | 2025 | | |
| Dilution susceptibility testing method evaluation for the combination of ceftibuten and avibactam against Enterobacterales. | Walser ON, Howland J, Jankowski K, Kennedy-Mendez A, Stone GG, Pillar CM, Hufnagel DA. | J Clin Microbiol | 10.1128/jcm.00072-25 | 2025 | | |
| The emerging concern of IMP variants being resistant to the only IMP-type metallo-beta-lactamase inhibitor, xeruborbactam. | Le Terrier C, Drusin SI, Nordmann P, Pitout J, Peirano G, Vila AJ, Moreno DM, Poirel L. | Antimicrob Agents Chemother | 10.1128/aac.00297-25 | 2025 | | |
| Tapping into Tapajos: antibacterial potential of fungal strains isolated from decaying wood in the Brazilian Amazon. | Canto ESM, Bentes VS, Silva MJA, Lima ES, Silva DR, Nunez CV, Cortez ACA, Souza ES, Souza JVB. | Braz J Biol | 10.1590/1519-6984.275573 | 2023 | | |
| Transcriptome | Biophysical and transcriptomic characterization of LL-37-derived antimicrobial peptide targeting multidrug-resistant Escherichia coli and ESKAPE pathogens. | Eladl O. | Sci Rep | 10.1038/s41598-025-22890-7 | 2025 | |
| Relative inhibitory activities of the broad-spectrum beta-lactamase inhibitor xeruborbactam in comparison with taniborbactam against metallo-beta-lactamases produced in Escherichia coli and Pseudomonas aeruginosa. | Le Terrier C, Freire S, Viguier C, Findlay J, Nordmann P, Poirel L. | Antimicrob Agents Chemother | 10.1128/aac.01570-23 | 2024 | | |
| Structure and mechanism of taniborbactam inhibition of the cefepime-hydrolyzing, partial R2-loop deletion Pseudomonas-derived cephalosporinase variant PDC-88. | Mack AR, Kumar V, Bethel CR, Taracila MA, Miller BA, Uehara T, Six DA, Papp-Wallace KM, van den Akker F, Bonomo RA. | Antimicrob Agents Chemother | 10.1128/aac.00078-25 | 2025 | | |
| Antimicrobial resistance profiles and detection of mecA, blaCTX-M-1, and blaSHV genes in bacteria among diabetic foot ulcer patients from selected referral hospitals in Uganda. | Namatovu A, Vahwere BM, Ntulume I, Ssebuufu R, Nalubega R, Pius T, Sikakulya FK, Agaba G, Seremba E, Kyamanywa P, Nasinyama GW. | BMC Infect Dis | 10.1186/s12879-025-11909-z | 2025 | | |
| Antimicrobial Potential of Metabolites in Fungal Strains Isolated from a Polluted Stream: Annulohypoxylon stygium WL1B5 Produces Metabolites against Extended-Spectrum Beta-Lactamase-Positive Escherichia coli. | Segundo WOPF, de Oliveira RS, Lima RM, Santiago PAL, de Oliveira LA, Cortez ACA, Lima ES, de Souza ES, Frickmann H, de Souza JVB. | Antibiotics (Basel) | 10.3390/antibiotics12010027 | 2022 | | |
| Spectrum of cefepime-taniborbactam coverage against 190 beta-lactamases defined in engineered isogenic Escherichia coli strains. | Uehara T, Chatwin CL, Miller B, Edwards M, Stevenson A, Colombo J, Six DA, Daigle DM, Moeck G, Boyd SA, Pevear DC. | Antimicrob Agents Chemother | 10.1128/aac.01699-24 | 2025 | | |
| Impact of surfactants and other body fluids on in vitro activity of a novel beta-lactamase inhibitor enmetazobactam in combination with cefepime against clinical isolates of Klebsiella pneumoniae. | Nussbaumer-Proll A, Eberl S, Belley A, Knechtle P, Huband MD, Huynh HK, Zeitlinger M. | J Antibiot (Tokyo) | 10.1038/s41429-022-00592-w | 2023 | | |
| Burkholderia pseudomallei PenI beta-lactamase and variants are potently inhibited by taniborbactam. | Mojica MF, Becka SA, Edwards M, Myers C, Uehara K, Uehara T, Hoshino T, Zeiser ET, Chatwin CL, Six DA, Bonomo RA, Papp-Wallace KM, Nukaga M. | Antimicrob Agents Chemother | 10.1128/aac.00787-25 | 2025 | | |
| Effect of modification of penicillin-binding protein 3 on susceptibility to ceftazidime-avibactam, imipenem-relebactam, meropenem-vaborbactam, aztreonam-avibactam, cefepime-taniborbactam, and cefiderocol of Escherichia coli strains producing broad-spectrum beta-lactamases. | Le Terrier C, Nordmann P, Buchs C, Poirel L. | Antimicrob Agents Chemother | 10.1128/aac.01548-23 | 2024 | | |
| Relative inhibitory activities of the broad-spectrum beta-lactamase inhibitor taniborbactam against metallo-beta-lactamases. | Le Terrier C, Viguier C, Nordmann P, Vila AJ, Poirel L. | Antimicrob Agents Chemother | 10.1128/aac.00991-23 | 2024 | | |
| Overview of changes in the Clinical and Laboratory Standards Institute Performance Standards for Antimicrobial Susceptibility Testing: M100 32nd and 33rd editions. | Schuetz AN, Ferrell A, Hindler JA, Humphries R, Bobenchik AM. | J Clin Microbiol | 10.1128/jcm.01623-23 | 2025 | | |
| Relative inhibitory activities of newly developed diazabicyclooctanes, boronic acid derivatives, and penicillin-based sulfone beta-lactamase inhibitors against broad-spectrum AmpC beta-lactamases. | Le Terrier C, Mlynarcik P, Sadek M, Nordmann P, Poirel L. | Antimicrob Agents Chemother | 10.1128/aac.00775-24 | 2024 | | |
| Sulbactam-durlobactam susceptibility test method development and quality control ranges for MIC and disk diffusion tests. | McLeod SM, Carter NM, Huband MD, Traczewski MM, Bradford PA, Miller AA. | J Clin Microbiol | 10.1128/jcm.01228-23 | 2024 | | |
| Broad spectrum of beta-lactamase coverage and potent antimicrobial activity of xeruborbactam in combination with meropenem against carbapenemase-producing Enterobacterales, including strains resistant to new beta-lactam/beta-lactamase inhibitor combinations. | Sanchez-Pena L, Rodriguez-Pallares S, Aja-Macaya P, Blanco-Martin T, Gonzalez-Pinto L, Perez-Rodriguez G, Le Terrier C, Portillo-Calderon I, Recacha E, Riazzo C, Vazquez-Ucha JC, Beceiro A, Aracil B, Oteo-Iglesias J, Martinez-Martinez L, Poirel L, Bou G, Arca-Suarez J. | Antimicrob Agents Chemother | 10.1128/aac.00533-25 | 2025 | | |
| Transmission of beta-lactamases in the pork food chain: A public health concern. | Rega M, Andriani L, Poeta A, Casadio C, Diegoli G, Bonardi S, Conter M, Bacci C. | One Health | 10.1016/j.onehlt.2023.100632 | 2023 | | |
| Multidrug-Resistant Enteropathogenic Escherichia coli Isolated from Diarrhoeic Calves, Milk, and Workers in Dairy Farms: A Potential Public Health Risk. | Eldesoukey IE, Elmonir W, Alouffi A, Beleta EIM, Kelany MA, Elnahriry SS, Alghonaim MI, alZeyadi ZA, Elaadli H. | Antibiotics (Basel) | 10.3390/antibiotics11080999 | 2022 | | |
| Anti-Infective Properties, Cytotoxicity, and In Silico ADME Parameters of Novel 4'-(Piperazin-1-yl)benzanilides. | Hermann T, Harzl S, Wallner R, Prettner E, Pferschy-Wenzig EM, Cal M, Maser P, Weis R. | Pharmaceuticals (Basel) | 10.3390/ph18071004 | 2025 | | |
| Enzymology | Evaluation of Dilution Susceptibility Testing Methods for Aztreonam in Combination with Avibactam against Enterobacterales. | Kelley CJ, Kennedy-Mendez A, Walser ON, Thwaites MT, Arhin FF, Pillar CM, Hufnagel DA. | Microbiol Spectr | 10.1128/spectrum.03601-22 | 2022 | |
| Assessment of the activity and mechanisms of resistance to cefiderocol and combinations of beta-lactams and the novel beta-lactamase inhibitors avibactam, taniborbactam, zidebactam, nacubactam, xeruborbactam, and ANT3310 in emerging double-carbapenemase-producing Enterobacterales. | Blanco-Martin T, Lopez-Hernandez I, Aracil B, Gonzalez-Pinto L, Aja-Macaya P, Alonso-Garcia I, Rodriguez-Pallares S, Sanchez-Pena L, Outeda-Garcia M, Perez-Vazquez M, Vazquez-Ucha JC, Beceiro A, Pascual A, Bou G, Lopez-Cerero L, Oteo-Iglesias J, Arca-Suarez J, GEMARA-SEIMC/CIBERINFEC Study Group on the activity and resistance mechanisms to new b-lactams and b-lactamase inhibitors (PROTECT). | Antimicrob Agents Chemother | 10.1128/aac.00924-24 | 2024 | | |
| Predominance of multidrug-resistant bacteria causing urinary tract infections among symptomatic patients in East Africa: a call for action. | Maldonado-Barragan A, Mshana SE, Keenan K, Ke X, Gillespie SH, Stelling J, Maina J, Bazira J, Muhwezi I, Mushi MF, Green DL, Kesby M, Lynch AG, Sabiiti W, Sloan DJ, Sandeman A, Kiiru J, Asiimwe B, Holden MTG. | JAC Antimicrob Resist | 10.1093/jacamr/dlae019 | 2024 | | |
| Trends of beta-Lactamase Occurrence Among Escherichia coli and Klebsiella pneumoniae in United States Hospitals During a 5-Year Period and Activity of Antimicrobial Agents Against Isolates Stratified by beta-Lactamase Type. | Castanheira M, Kimbrough JH, DeVries S, Mendes RE, Sader HS. | Open Forum Infect Dis | 10.1093/ofid/ofad038 | 2023 | | |
| In vitro activity of cefepime/taniborbactam and comparator agents against Gram-negative bacterial bloodstream pathogens recovered from patients with cancer. | Gerges B, Rosenblatt J, Truong YL, Jiang Y, Shelburne SA, Chaftari AM, Hachem R, Raad I. | JAC Antimicrob Resist | 10.1093/jacamr/dlae060 | 2024 | | |
| Pathogenicity | Development of Broth Microdilution MIC and Disk Diffusion Antimicrobial Susceptibility Test Quality Control Ranges for the Combination of Cefepime and the Novel beta-Lactamase Inhibitor Enmetazobactam. | Belley A, Huband MD, Fedler KA, Watters AA, Flamm RK, Shapiro S, Knechtle P. | J Clin Microbiol | 10.1128/jcm.00607-19 | 2019 | |
| Impact of chromosomally encoded resistance mechanisms and transferable beta-lactamases on the activity of cefiderocol and innovative beta-lactam/beta-lactamase inhibitor combinations against Pseudomonas aeruginosa. | Gonzalez-Pinto L, Alonso-Garcia I, Blanco-Martin T, Camacho-Zamora P, Fraile-Ribot PA, Outeda-Garcia M, Lasarte-Monterrubio C, Guijarro-Sanchez P, Maceiras R, Moya B, Juan C, Vazquez-Ucha JC, Beceiro A, Oliver A, Bou G, Arca-Suarez J. | J Antimicrob Chemother | 10.1093/jac/dkae263 | 2024 | | |
| Pathogenicity | The anti-virulence effect of cranberry active compound proanthocyanins (PACs) on expression of genes in the third-generation cephalosporin-resistant Escherichia coli CTX-M-15 associated with urinary tract infection. | Samarasinghe S, Reid R, Al-Bayati M. | Antimicrob Resist Infect Control | 10.1186/s13756-019-0637-9 | 2019 | |
| Extended-spectrum beta-lactamases among Klebsiella pneumoniae from Iraqi patients with community-acquired pneumonia. | Raouf FEA, Benyagoub E, Alkhudhairy MK, Akrami S, Saki M. | Rev Assoc Med Bras (1992) | 10.1590/1806-9282.20220222 | 2022 | | |
| Prevalence of carbapenemase genes among carbapenem-nonsusceptible Enterobacterales collected in US hospitals in a five-year period and activity of ceftazidime/avibactam and comparator agents. | Castanheira M, Deshpande LM, Mendes RE, Doyle TB, Sader HS. | JAC Antimicrob Resist | 10.1093/jacamr/dlac098 | 2022 | | |
| Prevalence, antimicrobial resistance, and genotyping of Shiga toxin-producing Escherichia coli in foods of cattle origin, diarrheic cattle, and diarrheic humans in Egypt. | Elmonir W, Shalaan S, Tahoun A, Mahmoud SF, Remela EMA, Eissa R, El-Sharkawy H, Shukry M, Zahran RN. | Gut Pathog | 10.1186/s13099-021-00402-y | 2021 | | |
| In vitro potency of xeruborbactam in combination with multiple beta-lactam antibiotics in comparison with other beta-lactam/beta-lactamase inhibitor (BLI) combinations against carbapenem-resistant and extended-spectrum beta-lactamase-producing Enterobacterales. | Lomovskaya O, Castanheira M, Lindley J, Rubio-Aparicio D, Nelson K, Tsivkovski R, Sun D, Totrov M, Loutit J, Dudley M. | Antimicrob Agents Chemother | 10.1128/aac.00440-23 | 2023 | | |
| Pathogenicity | Determination of Disk Diffusion and MIC Quality Control Guidelines for High-Dose Cefepime-Tazobactam (WCK 4282), a Novel Antibacterial Combination Consisting of a beta-Lactamase Inhibitor and a Fourth-Generation Cephalosporin. | Riedel S, Huband MD, Sader HS, Flamm RK, Jones RN. | J Clin Microbiol | 10.1128/jcm.00788-17 | 2017 | |
| Vaborbactam increases meropenem susceptibility in Pseudomonas aeruginosa clinical isolates displaying MexXY and AmpC upregulation. | Castanheira M, Doyle TB, Hubler CM, DeVries S, Shortridge D. | mSphere | 10.1128/msphere.00162-23 | 2023 | | |
| Multidrug-Resistant ESBL-Producing E. coli in Clinical Samples from the UK. | Ibrahim DR, Dodd CER, Stekel DJ, Meshioye RT, Diggle M, Lister M, Hobman JL. | Antibiotics (Basel) | 10.3390/antibiotics12010169 | 2023 | | |
| Antibiotic and Metal Resistance in Escherichia coli Isolated from Pig Slaughterhouses in the United Kingdom. | Yang H, Wei SH, Hobman JL, Dodd CER. | Antibiotics (Basel) | 10.3390/antibiotics9110746 | 2020 | | |
| Existence of Multiple ESBL Genes among Phenotypically Confirmed ESBL Producing Klebsiella pneumoniae and Escherichia coli Concurrently Isolated from Clinical, Colonization and Contamination Samples from Neonatal Units at Bugando Medical Center, Mwanza, Tanzania. | Silago V, Kovacs D, Samson H, Seni J, Matthews L, Oravcova K, Lupindu AM, Hoza AS, Mshana SE. | Antibiotics (Basel) | 10.3390/antibiotics10050476 | 2021 | | |
| Pathogenicity | Antibacterial apple cider vinegar eradicates methicillin resistant Staphylococcus aureus and resistant Escherichia coli. | Yagnik D, Ward M, Shah AJ. | Sci Rep | 10.1038/s41598-020-78407-x | 2021 | |
| Prevalence of ESbetaL, AmpC and Colistin-Resistant E. coli in Meat: A Comparison between Pork and Wild Boar. | Rega M, Carmosino I, Bonilauri P, Frascolla V, Vismarra A, Bacci C. | Microorganisms | 10.3390/microorganisms9020214 | 2021 | | |
| Effect of Colistin, Fosfomycin and Meropenem/Vaborbactam on Carbapenem-Resistant Enterobacterales in Egypt: A Cross-Sectional Study. | Shrief R, El-Ashry AH, Mahmoud R, El-Mahdy R. | Infect Drug Resist | 10.2147/idr.s385411 | 2022 | | |
| Impact of Sediment Concentration on the Survival of Wastewater-Derived blaCTX-M-15-Producing E. coli, and the Implications for Dispersal into Estuarine Waters. | Bashawri YM, Robins P, Cooper DM, McDonald JE, Jones DL, Williams AP. | Int J Environ Res Public Health | 10.3390/ijerph17207608 | 2020 | | |
| Pathogenicity | Antimicrobial Susceptibility of Pseudomonas aeruginosa to Ceftazidime-Avibactam, Ceftolozane-Tazobactam, Piperacillin-Tazobactam, and Meropenem Stratified by U.S. Census Divisions: Results from the 2017 INFORM Program. | Sader HS, Flamm RK, Carvalhaes CG, Castanheira M. | Antimicrob Agents Chemother | 10.1128/aac.01587-18 | 2018 | |
| VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-beta-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa. | Hamrick JC, Docquier JD, Uehara T, Myers CL, Six DA, Chatwin CL, John KJ, Vernacchio SF, Cusick SM, Trout REL, Pozzi C, De Luca F, Benvenuti M, Mangani S, Liu B, Jackson RW, Moeck G, Xerri L, Burns CJ, Pevear DC, Daigle DM. | Antimicrob Agents Chemother | 10.1128/aac.01963-19 | 2020 | | |
| Pathogenicity | Increasing frequency of OXA-48-producing Enterobacterales worldwide and activity of ceftazidime/avibactam, meropenem/vaborbactam and comparators against these isolates. | Castanheira M, Doyle TB, Collingsworth TD, Sader HS, Mendes RE. | J Antimicrob Chemother | 10.1093/jac/dkab306 | 2021 | |
| Pathogenicity | A pilot study of the in vitro antimicrobial activity and in vivo residual activity of chlorhexidine and acetic acid/boric acid impregnated cleansing wipes. | Rafferty R, Robinson VH, Harris J, Argyle SA, Nuttall TJ. | BMC Vet Res | 10.1186/s12917-019-2098-z | 2019 | |
| Pathogenicity | Natural antimicrobial peptide complexes in the fighting of antibiotic resistant biofilms: Calliphora vicina medicinal maggots. | Gordya N, Yakovlev A, Kruglikova A, Tulin D, Potolitsina E, Suborova T, Bordo D, Rosano C, Chernysh S. | PLoS One | 10.1371/journal.pone.0173559 | 2017 | |
| Characterization of Enterobacter cloacae and Citrobacter freundii species complex isolates with decreased susceptibility to cephalosporins from United States hospitals and activity of ceftazidime/avibactam and comparator agents. | Sader HS, Mendes RE, Doyle TB, Davis AP, Castanheira M. | JAC Antimicrob Resist | 10.1093/jacamr/dlab136 | 2021 | | |
| Activity of cefepime/taniborbactam and comparators against whole genome sequenced ertapenem-non-susceptible Enterobacterales clinical isolates: CANWARD 2007-19. | Golden AR, Baxter MR, Karlowsky JA, Mataseje L, Mulvey MR, Walkty A, Bay D, Schweizer F, Lagace-Wiens PRS, Adam HJ, Zhanel GG. | JAC Antimicrob Resist | 10.1093/jacamr/dlab197 | 2022 | | |
| Antibiotic Susceptibility of NDM-Producing Enterobacterales Collected in the United States in 2017 and 2018. | Lutgring JD, Balbuena R, Reese N, Gilbert SE, Ansari U, Bhatnagar A, Boyd S, Campbell D, Cochran J, Haynie J, Ilutsik J, Longo C, Swint S, Rasheed JK, Brown AC, Karlsson M. | Antimicrob Agents Chemother | 10.1128/aac.00499-20 | 2020 | | |
| Pathogenicity | WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide in 2015. | Sader HS, Castanheira M, Huband M, Jones RN, Flamm RK. | Antimicrob Agents Chemother | 10.1128/aac.00072-17 | 2017 | |
| The molecular characterisation of Escherichia coli K1 isolated from neonatal nasogastric feeding tubes. | Alkeskas A, Ogrodzki P, Saad M, Masood N, Rhoma NR, Moore K, Farbos A, Paszkiewicz K, Forsythe S. | BMC Infect Dis | 10.1186/s12879-015-1210-7 | 2015 | | |
| Ceftibuten-Ledaborbactam Activity against Multidrug-Resistant and Extended-Spectrum-beta-Lactamase-Positive Clinical Isolates of Enterobacterales from a 2018-2020 Global Surveillance Collection. | Karlowsky JA, Wise MG, Hackel MA, Pevear DC, Moeck G, Sahm DF. | Antimicrob Agents Chemother | 10.1128/aac.00934-22 | 2022 | | |
| Pathogenicity | Comparative Activities of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Enterobacteriaceae Isolates Producing Extended-Spectrum beta-Lactamases from U.S. Hospitals. | Castanheira M, Doyle TB, Mendes RE, Sader HS. | Antimicrob Agents Chemother | 10.1128/aac.00160-19 | 2019 | |
| Pathogenicity | Genetic characterization of TEM-type ESBL-associated antibacterial resistance in Enterobacteriaceae in a tertiary hospital in Ghana. | Oduro-Mensah D, Obeng-Nkrumah N, Bonney EY, Oduro-Mensah E, Twum-Danso K, Osei YD, Sackey ST. | Ann Clin Microbiol Antimicrob | 10.1186/s12941-016-0144-2 | 2016 | |
| Pathogenicity | Multidrug-resistant organisms, wounds and topical antimicrobial protection. | Bowler PG, Welsby S, Towers V, Booth R, Hogarth A, Rowlands V, Joseph A, Jones SA. | Int Wound J | 10.1111/j.1742-481x.2012.00991.x | 2012 | |
| Microbiological Characterization of VNRX-5236, a Broad-Spectrum beta-Lactamase Inhibitor for Rescue of the Orally Bioavailable Cephalosporin Ceftibuten as a Carbapenem-Sparing Agent against Strains of Enterobacterales Expressing Extended-Spectrum beta-Lactamases and Serine Carbapenemases. | Chatwin CL, Hamrick JC, Trout REL, Myers CL, Cusick SM, Weiss WJ, Pulse ME, Xerri L, Burns CJ, Moeck G, Daigle DM, John K, Uehara T, Pevear DC. | Antimicrob Agents Chemother | 10.1128/aac.00552-21 | 2021 | | |
| Multidrug-resistant Escherichia coli from canine urinary tract infections tend to have commensal phylotypes, lower prevalence of virulence determinants and ampC-replicons. | Wagner S, Gally DL, Argyle SA. | Vet Microbiol | 10.1016/j.vetmic.2014.01.003 | 2014 | | |
| Enzymology | Pharmacodynamics of Cefepime Combined with the Novel Extended-Spectrum-beta-Lactamase (ESBL) Inhibitor Enmetazobactam for Murine Pneumonia Caused by ESBL-Producing Klebsiella pneumoniae. | Johnson A, McEntee L, Farrington N, Kolamunnage-Dona R, Franzoni S, Vezzelli A, Massimiliano M, Knechtle P, Belley A, Dane A, Drusano G, Das S, Hope W. | Antimicrob Agents Chemother | 10.1128/aac.00180-20 | 2020 | |
| Antimicrobial susceptibility and molecular epidemiology of extended-spectrum beta-lactamase-producing Enterobacteriaceae from intensive care units at Hamad Medical Corporation, Qatar. | Sid Ahmed MA, Bansal D, Acharya A, Elmi AA, Hamid JM, Sid Ahmed AM, Chandra P, Ibrahim E, Sultan AA, Doiphode S, Bilal NE, Deshmukh A. | Antimicrob Resist Infect Control | 10.1186/s13756-016-0103-x | 2016 | | |
| Pathogenicity | Antimicrobial Activity of High-Proportion Cefepime-Tazobactam (WCK 4282) against a Large Number of Gram-Negative Isolates Collected Worldwide in 2014. | Sader HS, Castanheira M, Mendes RE, Flamm RK, Jones RN. | Antimicrob Agents Chemother | 10.1128/aac.02409-16 | 2017 | |
| Quality control for diagnostic oral microbiology laboratories in European countries. | Rautemaa-Richardson R, der Reijden Wa WA, Dahlen G, Smith AJ. | J Oral Microbiol | 10.3402/jom.v3i0.8395 | 2011 | |
How to citeIf you want to cite this particular strain cite the following doi:
https://doi.org/10.13145/bacdive154145.20251217.10
When using BacDive for research please cite the following paper
BacDive in 2025: the core database for prokaryotic strain data
License